Skip to content
New: free dose calculator with 14 peptide presets. No signup.
Peptides Academy

BPC-157 + SS-31 + Angiotensin-1-7 + MOTS-c Vascular Health Stack

A theoretical peptide combination discussed for endothelial and circulatory support — pairing angiogenesis and vasodilatory rationale with mitochondrial peptides aimed at vascular metabolic stress. The evidence is largely preclinical, no controlled trial has tested this combination, and cardiovascular risk should be managed with proven medical care.

Quick Comparison

PropertypeptideThe Vascular Health Stack: BPC-157 + SS-31 + Angiotensin-1-7 + MOTS-c
SourceSalmon DNA fragmentsVarious sources
Primary MechanismA2A receptor activation, DNA repairVaries by ingredient
Key BenefitsTissue regeneration, anti-inflammation, collagen boostMultiple skin benefits
Best Time to ApplyAM or PMAM or PM
Can Combine?Generally compatible — check specific guidelines.

How to Use Together

No validated protocol exists; these are research compounds and the combination is clinically untested for vascular health. Representative community approaches: BPC-157 250–500 mcg subcutaneously daily in 4–6 week cycles for its proposed angiogenic and vascular-repair rationale; SS-31 (elamipretin) is an investigational mitochondria-targeting peptide that in research settings has been given by injection under supervision, not self-dosed; Angiotensin-(1-7) is a short-acting peptide of the protective arm of the renin-angiotensin system, studied mostly by infusion in controlled trials rather than as a self-administered agent; MOTS-c is a mitochondrial-derived peptide explored preclinically for metabolic and endothelial effects, sometimes used subcutaneously in the community. This stack acts on blood-pressure and cardiovascular pathways, so it is not something to layer onto cardiac medications casually. Any vascular concern should be assessed and managed by a clinician first.

Safety Notes

This stack directly touches cardiovascular physiology, which makes unsupervised use particularly risky. Angiotensin-(1-7) acts on the renin-angiotensin system and could interact unpredictably with blood-pressure medications (ACE inhibitors, ARBs), causing hypotension or other effects; it should not be combined with antihypertensives without medical oversight. SS-31 remains investigational and has only been used in supervised clinical research. Established cardiovascular risk factors — hypertension, high LDL cholesterol, diabetes, smoking, atrial fibrillation — have proven treatments that dramatically reduce heart attack and stroke risk, and no peptide should replace them. Chest pain, shortness of breath, palpitations, or leg swelling require urgent medical evaluation, not self-experimentation. Anyone with known heart or vascular disease, or on cardiac medication, should not use this stack without a cardiologist's input.

Recommended Products (4)

Frequently Asked Questions

Can this stack prevent heart attacks or strokes?
No, and it should never be used with that expectation. Heart attack and stroke prevention rests on well-proven measures — controlling blood pressure and LDL cholesterol (often with statins), managing diabetes, not smoking, treating atrial fibrillation, and antiplatelet therapy where indicated — all backed by large clinical trials. This peptide combination has no such evidence and is a mechanistic hypothesis at best. Relying on it in place of proven cardiovascular care would be dangerous. If you are concerned about cardiovascular risk, a clinician can assess and treat it with methods that actually reduce events.
What is the endothelium and why does this stack target it?
The endothelium is the thin layer of cells lining blood vessels; it regulates vascular tone, clotting, and inflammation, and its dysfunction is an early step in atherosclerosis. The rationale for this stack is that its peptides might support endothelial function through angiogenesis (BPC-157), protective renin-angiotensin signaling (Angiotensin-(1-7)), and mitochondrial support (SS-31, MOTS-c). This is biologically reasonable framing, but 'supporting the endothelium' with these specific research peptides has not been shown to improve real vascular outcomes in controlled human studies.
Has any clinical trial tested this combination for vascular health?
No controlled trial has tested this four-peptide combination for vascular or circulatory health. The individual peptides come from separate research lines that are mostly preclinical or early-stage, and some (like SS-31 and Angiotensin-(1-7)) have been studied only in supervised clinical settings by infusion or injection. Combining all four is a community hypothesis without synergy or safety data. Any online claims about this stack improving circulation should be treated as unproven, and cardiovascular decisions should rest on established evidence.
Is Angiotensin-(1-7) safe to combine with blood pressure medication?
This is a specific safety concern and the answer is that it should not be combined without medical supervision. Angiotensin-(1-7) belongs to the protective, vasodilatory arm of the renin-angiotensin system, and adding it on top of ACE inhibitors or ARBs could compound blood-pressure-lowering effects unpredictably, risking hypotension. Its human use has largely been by controlled infusion in research, not chronic self-administration. If you take antihypertensives or have blood-pressure issues, do not add this peptide on your own — a physician needs to weigh in on any interaction.
What roles do SS-31 and MOTS-c play here?
Both are mitochondria-related peptides, included on the theory that vascular cells under metabolic stress suffer mitochondrial dysfunction. SS-31 (elamipretin) targets the inner mitochondrial membrane and has been investigated in trials for conditions involving impaired energy production. MOTS-c is a mitochondrial-derived peptide studied preclinically for metabolic regulation and possible endothelial effects. The rationale is that improving vascular cell energetics could support function, but this remains largely preclinical, and neither has established evidence for improving human vascular outcomes as used in this stack.
Could BPC-157 improve circulation?
BPC-157 has preclinical data suggesting angiogenic and vascular-protective properties, which is the basis for its inclusion, but the vast majority of that work is in animals, not controlled human vascular studies. Extrapolating from rodent healing models to meaningful improvements in human circulation is a large leap. There is no robust human evidence that BPC-157 improves circulation or treats vascular disease. Its inclusion here is a mechanistic rationale, not a proven effect, and it should not be relied upon for any cardiovascular condition.
I have high blood pressure — should I try this instead of my medication?
No. Hypertension is one of the most treatable major risk factors for stroke and heart disease, and its treatments — lifestyle changes plus medications like ACE inhibitors, ARBs, calcium channel blockers, and diuretics — are backed by extensive trial evidence showing they prevent serious events. Stopping proven medication to try unproven peptides could raise your blood pressure and your risk of stroke and heart attack. Please continue your prescribed treatment and discuss any interest in peptides with your physician, who can also check for interactions.
What proven steps actually protect vascular health?
The strongest-evidence measures are not smoking, keeping blood pressure and LDL cholesterol controlled, staying physically active (aerobic exercise improves endothelial function directly), maintaining a healthy weight, managing blood sugar, a Mediterranean-style diet, limiting alcohol, and managing stress and sleep. Where risk is elevated, statins and blood-pressure medications meaningfully reduce cardiovascular events. These interventions are well-studied and address the same vascular biology this stack targets, far more reliably. They should be the foundation, with peptides at most an unproven and secondary consideration.
Are these peptides approved cardiovascular treatments?
None of them is an approved cardiovascular treatment for general use. SS-31 and Angiotensin-(1-7) have been studied as investigational agents in controlled settings, and BPC-157 and MOTS-c are sold as research compounds rather than medicines. Because they are not manufactured or regulated as cardiovascular drugs, using them this way is off-label and experimental, with no guarantee of purity or dosing accuracy. Approved, evidence-based treatments exist for the major vascular conditions people worry about, and those should be managed with a clinician rather than replaced by research peptides.

Other peptide Ingredient Combinations

The Anti-Aging Stack: GHK-Cu + Epitalon

GHK-Cu and Epitalon target two distinct hallmarks of aging — extracellular matrix degradation and te

The Athletic Performance Stack: IGF-1 LR3 + Ipamorelin + BPC-157

The athletic performance stack layers three peptides with distinct but complementary mechanisms to s

The Autoimmune Stack: KPV + BPC-157 + Thymosin Alpha-1 + Low-Dose Naltrexone

A four-component protocol addressing autoimmune dysregulation through complementary immunomodulatory

The Bone Health Stack: BPC-157 + Abaloparatide + Collagen Peptides

A three-component protocol addressing bone mineral density and bone quality. Abaloparatide is a synt

The Cardiac Protection Stack: TB-500 + SS-31 + Humanin

A three-peptide cardiovascular support stack targeting myocardial repair (TB-500), mitochondrial car

The Cognitive Stack: Semax + Selank

The classic Russian nootropic peptide pairing. Semax (an ACTH 4-10 analog) enhances BDNF expression

The Detox Support Stack: BPC-157 + KPV + LL-37 + Larazotide

A four-peptide combination addressing gut barrier integrity, systemic inflammation, and antimicrobia

The Endurance Stack: MOTS-c + SS-31 + BPC-157 + AOD-9604

A community-derived peptide combination discussed by endurance athletes for mitochondrial capacity,

The Eye Health Stack: Thymosin Beta-4 + BPC-157 + SS-31 + GHK-Cu

A theoretical peptide combination discussed for ocular surface and retinal support — dry eye, cornea

The Fat Loss Stack: Tesamorelin + CJC-1295/Ipamorelin

Tesamorelin and CJC-1295/Ipamorelin both target the GH axis but through complementary timing and rec

The Fertility Stack: Kisspeptin-10 + Gonadorelin + Oxytocin

A three-peptide protocol targeting the hypothalamic-pituitary-gonadal (HPG) axis at multiple levels.

The GH Stack: CJC-1295 + Ipamorelin

The dual-pathway growth-hormone stack. CJC-1295 (GHRH analog) opens the pituitary somatotroph; Ipamo

The Gut-Brain Stack: BPC-157 + KPV + Selank + Larazotide

A community-derived peptide combination built around the gut-brain axis — pairing intestinal barrier

The Gut Healing Stack: BPC-157 + KPV + Larazotide

The gut healing stack combines three peptides targeting distinct aspects of intestinal repair: BPC-1

The Hair Restoration Stack: GHK-Cu + Thymosin Beta-4

GHK-Cu and Thymosin Beta-4 (TB-500) target complementary mechanisms in hair follicle biology — coppe

The Healing Stack: BPC-157 + TB-500

The canonical regenerative-peptide pairing. BPC-157 and TB-500 operate through non-overlapping biolo

Immune Support Stack

A combination approach targeting immune function through three complementary mechanisms: adaptive im

The Joint Repair Stack: BPC-157 + Pentosan Polysulfate + TB-500

A comprehensive joint-repair protocol targeting all layers of joint pathology: BPC-157 for periartic

The Longevity Stack: Epitalon + MOTS-c + SS-31

Three peptides targeting different hallmarks of aging: Epitalon for telomerase activation and pineal

The Men's Hormone Stack: CJC-1295/Ipamorelin + Gonadorelin + Kisspeptin-10

A three-peptide protocol designed to optimize the male hormonal axis without exogenous testosterone.

The Menopause Support Stack: Kisspeptin-10 + Epitalon + BPC-157 + GHK-Cu

A community-derived peptide combination sometimes discussed for the constellation of complaints arou

The Metabolic Stack: GLP-1 + GHS

A newer 'metabolic recomposition' pairing some practitioners use: a GLP-1 agonist for appetite and t

The Mitochondrial Stack: SS-31 + MOTS-c + Humanin

Three mitochondria-targeted peptides addressing different aspects of mitochondrial dysfunction. SS-3

The Mood & Anxiety Stack: Selank + NA-Selank-Amidate + DSIP + Oxytocin

A four-peptide anxiolytic and mood-stabilizing protocol. Selank modulates GABA and serotonin signali

The Neuroprotection Stack: Cerebrolysin + Semax + Pinealon

The neuroprotection stack combines three neuropeptide approaches with complementary mechanisms — cer

The Nootropic Stack: Semax + Selank + GH-Axis Support

A three-tier nootropic peptide stack targeting cognitive performance through complementary mechanism

The Post-Surgery Recovery Stack: BPC-157 + TB-500 + Thymosin Alpha-1

The post-surgery recovery stack combines the established BPC-157 + TB-500 tissue-repair pairing with

The Sexual Health Stack: PT-141 + Kisspeptin-10

PT-141 and Kisspeptin-10 target complementary aspects of sexual function — central desire pathways a

The Skin Rejuvenation Stack: GHK-Cu + GH-Axis + Collagen

A multi-level skin rejuvenation protocol combining topical signaling (GHK-Cu), systemic GH-axis elev

The Sleep Stack: DSIP + Ipamorelin

DSIP (Delta Sleep-Inducing Peptide) and ipamorelin target complementary aspects of sleep optimizatio

The Stress Resilience Stack: Selank + DSIP + Semax

A three-peptide stack targeting different dimensions of the stress response: Selank for anxiolysis a

The Tendon Repair Stack: BPC-157 + TB-500 + GHK-Cu

A three-peptide protocol targeting tendon biology specifically. BPC-157 upregulates growth hormone r

The Thymic Regeneration Stack: Thymosin Alpha-1 + Thymalin + Thymulin

Three thymic peptides targeting the age-related involution of the thymus gland. Thymosin alpha-1 enh

The Weight Loss Stack: Semaglutide/Tirzepatide + Tesamorelin

This weight loss stack combines GLP-1 receptor agonist therapy (semaglutide or tirzepatide) with the

The Women's Hormonal Stack: Kisspeptin + BPC-157 + Thymosin Alpha-1

A three-peptide combination addressing women's hormonal health through hypothalamic signaling restor

The Wound Care Stack: BPC-157 + GHK-Cu + TB-500 + Collagen Peptides

A four-component protocol covering the full wound healing cascade. BPC-157 promotes angiogenesis and

Browse All peptide Products

Search

Search across products, blog posts, wiki articles, and more.